Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arcapta Quality Of Life Data For High Dose Cannot Overcome Efficacy Questions

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pulmonary-Allergy Drugs Advisory Committee endorses approval of the 75 mcg dose of indacaterol but recommends against approval of Novartis' preferred 150 mcg dose of the chronic obstructive pulmonary disease drug.

You may also be interested in...



Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose

Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.

Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose

Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.

Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks

The agency will also ask its Arthritis Advisory Committee at a June 21 meeting whether the sponsor should explore lower doses for the interleukin-1 beta inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel